Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: David Graham who wrote (3340)	2/8/2000 7:30:00 PM
From: Mark Bartlett	Read Replies (2) \| Respond to of 14101

David, <<What does the thread think?>> Well .... DMX has never been about promo (perhaps a little too much that way) but my sense is that all of the duckies are lining up, and their moment in the sun is coming. The buying today was serious $$$ -- some big buys went through. My 2 cents .... well as of today, we'll make that 4 <G> MB

To: David Graham who wrote (3340)	2/8/2000 8:28:00 PM
From: john.d	Read Replies (1) \| Respond to of 14101

David, "I want to take a survey. Being a bit of a contrarian, I wonder how much of this run-up is due to the fact that almost every pharma/biotech in Canada is bulling along and how much is due to impending news." one way to analyze is to ask ourselves what price would DMX be if the Biotech sector corrected back to levels at the turn of the New Millenium. Without news, I believe DMX would fall back, however I doubt that it would fall back to the 4's. I believe that Peter's road show has helped bring in new buyers and I suspect there were buyers (now shareholders) on the sidelines (investing elsewhere) waiting for the run, which has begun. With all the pending news expected this year, I think we can expect some decent strength no matter what happens to the sector. In fact, if we have a major correction in the market, with FDA approval in hand, I'll be buying. Hope this helps John

To: David Graham who wrote (3340)	2/8/2000 9:07:00 PM
From: Herb Duncan	Respond to of 14101

There may be some merit to your comments, take a look at SDI.

To: David Graham who wrote (3340)	2/8/2000 9:24:00 PM
From: Mike Jubian	Read Replies (2) \| Respond to of 14101

David, <<I wonder how much of this run-up is due to the fact that almost every pharma/biotech in Canada is bulling along and how much is due to impending news.>> It's a combination of both, Investors/Analysts are all searching to find undervalued companies. This has captured the attention of pharma/biotechs as they get closer to actually launching new products. With regards to impending news, read Wolf's post 3306. DMX has been very good keeping a tight lid on their day to day activities, it has been very difficult to predict which news release they will release and when. DMX is 90% held by retail investors (someone please correct me if I'm wrong) IMHO the trades in the past week might very well be a shift to institutional interest and accumulation. FWIW timing is everything, a combination of news releases with and a NASDAQ listing while the market is just right and who knows, we might also be worth 7 billion without earning a penny. Good Luck to all longs and new. MJ

To: David Graham who wrote (3340)	2/8/2000 9:54:00 PM
From: Montana Wildhack	Respond to of 14101

David, We need contrarians. In a few months the charts will show the truth. In all likelihood there is a percentage of the biotech crush affecting DMX; but, not as much as the stampede coming when Dimethaid makes announcement after announcement and then turns on the solid tap into that multi billion dollar Arthritis market. I doubt half the Bio's drawing interest right now will succeed at their business plans and am near certain the Dimethaid will. Dimethaid meets all the criteria on paper: -flush with cash -product at/near approvals -big drug firm relationships -few hurdles (manufacturing/inspection/translations) -sound management -no hint of hype -other products at least under development Look at the fungal product. What would you pay as lets say Glaxo/W to revolutionize this $1.5 billion market knowing the carrier achieves what has always blocked an efficient/safe cure? Whoever comes out with this sells 750 million US minimum first 12 months. It'll be the only thing in the market that actually works and as we all know I speak from personal experience as do others here. Dimethaid could hardly be in a better position thanks to the people there. We're watching for the manufacturing solution, then capacity, the details of the partnership deals, the UK labelling, price positioning, fungal product timeline, etc, etc. Nothing really showstopping. Lets point out for the new investors here, (there's bound to be a big bunch), that DMX only has the facilities inspection left in the FDA approval process for Pennsaid as a major hurdle. I hear your point David, but, I'm not buying. The placement was oversold. Those 2.5 million shares are up over 100% in a little over a month. I realize you're just presenting an argument and know all this; but, not everybody reading this does. Plus it hasn't exactly hurt that we keep reminding ourselves of the facts. Last point. I expect a 200% premium on any buyout offer. So no less than $26 if the offer is tomorrow. (No I haven't heard anything). All the best, Conan the librarian